Bio-Techne Corporation (NASDAQ: TECH) — A Quality Franchise That Ran Out of Growth and Sold Itself; Now a $73 Cash Arb

Independent equity research. Report date: July 3, 2026. Sector: Health Care · Life Sciences Tools & Services. Fiscal year ends June 30.

This article is for general information only and is not investment advice. With the single, explicitly-labeled exception of the “Author’s Take” block immediately below, it contains no buy/sell recommendation and no price target; the analysis discusses valuation only as embedded expectations, scenario analysis, and — because a definitive cash merger is pending — deal-spread arithmetic.

⚡ Author’s Take

This block is the author’s own subjective opinion. It is general information, not investment advice, and not a recommendation to buy or sell any security. The analysis in the sections below takes no position and issues no price target.

Verdict: this is no longer a fundamental equity — it is a merger-arbitrage instrument. HOLD-through-close for holders; a thin, deal-spread-only situation for new money; NOT a short. On June 25, 2026 Bio-Techne signed a definitive agreement to be acquired by Merck KGaA (Darmstadt / MilliporeSigma) for $73.00 per share in all cash (~$11.3B EV). At $70.83 the stock offers a ~3.1% gross spread to the deal price — roughly 4–5% annualized over an expected ~9–12 month close, plus ~$0.24 of dividends collected en route. That is a modest, low-beta yield if the deal closes, against a deal-break downside back to roughly $50–58 (−20% to −29%). The risk/reward is positive but unexciting; the entire question is antitrust.

Framing: risk-arbitrage / special situation — the terminal chapter of a five-year falling knife. Bio-Techne is a genuinely excellent reagent franchise (R&D Systems proteins and antibodies carry a real citation-and-consistency moat; 65–70% gross margins; low-30s% adjusted operating margins; ROIC that ran low-to-mid-teens before the cycle, now ~7.5%) that got trapped in the 2023–2026 biopharma-funding, academic/NIH, and China winter. Organic growth collapsed from ~20% to roughly zero, and the multiple de-rated from a ~19x-sales bubble ($131 in 2021) to a $43 low in May 2026. An activist (Ananym Capital) pushed for a sale on June 15; ten days later Merck agreed to buy the whole company at a 36% premium to the one-month VWAP. The takeout, not a fundamental inflection, is what ended the decline. My directional zone: worth $73 on completion; standalone unaffected value ~$50–58 (the deal-break landing zone); a topping bid is possible but low-odds and would face the same or worse antitrust. The $73 price itself is full — ~9.3x sales and ~25x adjusted EBITDA, the top of the tools group — a multiple only a strategic with ~$150M of synergies (and Merck’s own MilliporeSigma reagent platform) could rationalize. Do not mistake “below its own historical multiple” for “cheap”: on a standalone basis in this tape TECH is worth well under $73.

Conviction: medium. The deal is board-recommended, activist-endorsed, backed by a large $576M reverse termination fee (Merck bears the antitrust risk), and strategically obvious. The one live risk is a regulatory fight: Merck/MilliporeSigma directly overlaps Bio-Techne in reagents, proteins and bioprocessing, and Merck’s obligation is subject to a “Burdensome Condition” out (it need not accept divestitures it deems too onerous). Flips bullish: a competing/superior bid (a bump) or an early antitrust clearance that collapses the spread. Flips bearish: an FTC/EU second request signaling a burdensome-divestiture fight → Merck walks, pays the $576M, and the stock falls to the low-$50s.

Tag: “The knife that stopped falling because someone finally bought it.”

📈 Stock Price Action — Five-Year Event Map

Bio-Techne round-tripped an entire cycle: from a life-science-tools bubble peak of ~$131 (September 2021, ~19x sales) through a relentless four-and-a-half-year de-rating to a five-year low of $43.22 (May 15, 2026) — a −67% drawdown — before an activist campaign and then a cash takeover lifted it to $70.83 (July 2, 2026), now pinned just below the $73.00 deal price. The 52-week range is $43.22–$71.15; the stock sits ~46% below its own peak relative-strength but essentially at the announced acquisition price. Price moves below are Fact; the attributed drivers are Interpretation.

Cycle narrative. Events 1–5 are one long story: a premium compounder whose multiple inflated in the 2020–21 tools bubble and then deflated for four straight years as its end markets (biopharma R&D budgets, academic/NIH grants, China) went through a synchronized funding recession — the same winter that took Avantor, Repligen, Revvity and the broader tools group down 40–70%. Event 6 marked capitulation: a −2% organic quarter and a fresh five-year low. Events 7–8 are the resolution: an activist forced the board’s hand, and a strategic acquirer with an adjacent reagent/bioprocessing platform (Merck’s MilliporeSigma) stepped in at a full price. The stock now trades as a merger-arb security, decoupled from the tools tape until the deal closes or breaks.

1. Executive Summary

Bio-Techne is a Minneapolis-based life-science tools company built around two segments: Protein Sciences (~71% of revenue, ~43% segment operating margin; recombinant proteins, cytokines and growth factors, antibodies, and the Simple Western / Maurice / Ella analytical instruments — sold under the R&D Systems brand) and Diagnostics & Spatial Biology (~28%, ~6% segment operating margin; RNAscope in-situ hybridization and the COMET multiomic spatial platform, plus clinical controls and precision diagnostics). Roughly 80% of revenue is consumables — single-use proteins, antibodies, assays and reagents — a razor-and-razor-blade model with ~65–70% gross margins and best-in-class low-30s% adjusted operating margins.

The defining fact of this report is that on June 25, 2026, Bio-Techne agreed to be acquired by Merck KGaA (Darmstadt, Germany) for $73.00 per share in cash, an enterprise value of ~$11.3B (€9.9B) and a 36% premium to the one-month VWAP. The transaction is board-recommended, followed an activist (Ananym Capital) campaign to explore a sale, and is protected by a $230.5M company termination fee and a substantial $576.1M reverse termination fee borne by Merck for antitrust failure. Closing requires a majority shareholder vote and antitrust/foreign-investment clearances (HSR, EU, and others); the outside date is March 25, 2027, auto-extending to September 25, 2027 for antitrust.

The business the deal is buying is high-quality but cyclically depressed. Revenue grew from $739M (FY20) to $1,220M (FY25), but the trajectory tells the story: +26% (FY21), +19% (FY22), then +3%, +2%, +5% as the biopharma/academic/China funding winter hit. The latest quarter (Q3 FY26) was −2% organic — large pharma up double-digits for a sixth straight quarter, but emerging biotech down high-single-digits, the swing factor management expects to inflect in fiscal 2027. GAAP earnings are effectively uninterpretable (FY25 GAAP diluted EPS of $0.46 vs. adjusted $1.92, GAAP operating margin 8.4% vs. adjusted 31.6%), distorted by an $80.5M Exosome held-for-sale impairment, a $41.8M former-CEO arbitration charge, acquired-intangible amortization, and restructuring. On adjusted numbers the franchise remains a low-30s-operating-margin, ~$250M-FCF, sub-1x-levered business — though it carries a looming ~$1B obligation to buy out the rest of Wilson Wolf (a cell-therapy bioreactor maker) by end-2027. On close, that obligation becomes Merck’s.

For the current price, the market is underwriting near-certain deal completion. At $70.83 the ~3.1% spread to $73 implies a completion probability in the low-90s% against a ~$50–58 break level — a bet almost entirely on whether Merck and Bio-Techne can clear antitrust review of two overlapping reagent/bioprocessing platforms without a divestiture package Merck deems “burdensome.” This memo assesses the standalone business quality, the fairness of $73, and the deal-completion calculus, and takes no position.

2. Business Overview

Bio-Techne (formerly Techne Corporation; renamed 2014) is a ~50-year-old life-science tools company headquartered in Minneapolis. It develops and manufactures reagents, instruments and services used in biological research, drug discovery and development, cell & gene therapy manufacturing, and clinical diagnostics. It is not an “everything store” like Thermo Fisher; it occupies a deep, high-margin slice of the protein-science and spatial-biology workflow. It reports in two segments.

Protein Sciences (~73% of revenue; ~44% segment operating margin). This is the historical core and the profit engine. It comprises:

• Recombinant proteins, cytokines and growth factors — the R&D Systems catalog of 6,000+ proteins. Bio-Techne is the reference supplier of research-grade proteins, and is the only major vendor that runs bioassays validating how well each protein binds its receptor or stimulates cell activity. That validation lets it charge a premium (frequently 2–3x a competing vendor’s “same” protein), which pharma customers accept in discovery, where signal quality matters more than reagent cost.
• Antibodies and immunoassays — 400,000+ antibody types plus ELISA and multiplex immunoassays. Antibodies are the “barcodes for proteins” used to detect and quantify targets; good antibodies require good proteins, reinforcing the razor/razor-blade catalog.
• GMP proteins for cell & gene therapy — clinical-grade cytokines and growth factors used to expand and activate cells in cell-therapy manufacturing. This is a fast-growing (~+50% ex two large customers in Q3 FY26) vertical tied to the Wilson Wolf G-Rex bioreactor relationship.
• Proteomic analysis instruments — Simple Western (Jess/Wes), the Ella automated multiplex immunoassay platform (strong in neurodegeneration biomarkers, 3-yr assay CAGR ~50%, now CE-IVD marked), and Maurice (biologics characterization / QC). These are the “instrument” leg that pulls recurring consumable/cartridge revenue.

Diagnostics & Spatial Biology (~27% of revenue; ~12% segment operating margin). Renamed from “Diagnostics & Genomics.” It comprises:

• Spatial biology — the crown jewel is RNAscope (Advanced Cell Diagnostics / ACD), a patented in-situ hybridization chemistry for detecting RNA in intact tissue, plus the COMET multiomic spatial platform (from the 2023 Lunaphore acquisition). COMET grew >65% in Q3 FY26 with record backlog; RNAscope grew high-single-digits. Spatial biology is an emerging, structurally-growing niche increasingly used in translational and clinical research and, prospectively, AI-driven pathology (a published Providence Health/Microsoft “GigaTIME” framework used COMET-generated data).
• Diagnostics — clinical controls, calibrators and precision-diagnostic solutions (hematology, blood-gas, coagulation controls; molecular diagnostics). This is lumpy (concentrated large customers) and lower-margin.
• Exosome Diagnostics — a liquid-biopsy molecular-diagnostics business that Bio-Techne divested in fiscal 2026 (announced August 2025 for ~$15M, a steep markdown from its acquisition cost — see the relevant section). Its removal is a ~2% headwind to reported growth but improved segment margins (Diagnostics & Spatial Biology operating margin rose to 12.1% from 9.4%).

Revenue model and mix. Roughly three-quarters of revenue is consumables — single-use proteins, antibodies, assays and reagents recognized at a point in time on shipment — the recurring, high-margin base. The remainder is instruments (point-in-time) and services (over time). End markets: large pharma (the strongest, six consecutive quarters of double-digit growth), emerging biotech (the cyclical swing factor, currently soft), academia/government (NIH-sensitive, recently returned to growth), and cell & gene therapy / bioprocessing (fast-growing vertical). Geographically the business is global with a meaningful China presence that has posted four consecutive quarters of positive growth after a long slump. In April 2026 management consolidated ten brands into three — R&D Systems (all research and GMP reagents plus the proteomic-analysis instruments formerly branded ProteinSimple), Bio-Techne Spatial Biology (RNAscope + COMET), and Bio-Techne Diagnostics — to simplify the customer journey from discovery to clinic and improve digital/AI discoverability.

Verdict: A focused, consumables-heavy life-science tools business with a genuinely premium reagent core and an emerging spatial-biology growth engine, wrapped in a lower-margin, lumpier diagnostics tail. High-quality revenue base; the growth cyclicality is real and end-market-driven, not structural decay.

3. Industry Dynamics

Bio-Techne sits in life-science tools & services — the “picks-and-shovels” of biological research and biomanufacturing. Structurally, the reagent/consumables portion of this industry is one of the more attractive corners of health care: it is a recurring-revenue, high-gross-margin, fragmented-catalog business where the dollar cost of any individual reagent is trivial relative to the cost of a failed experiment or a mis-validated drug candidate, giving suppliers durable pricing power at the premium end. Barriers to entry in specific niches (validated proteins, patented spatial chemistries, GMP-grade manufacturing) are real. Marathon’s capital-cycle lens is favorable here: this is not a commoditizing, capacity-flooded industry; it is a specialty-consumables oligopoly with rational supply.

But the industry is cyclical on the demand side, and the last three years proved it. Roughly 2023–2026 saw a synchronized funding recession across the three big customer pools:

• Biopharma R&D budgets tightened as large pharma optimized spend and, more acutely, emerging biotech funding froze (venture and public-market capital for small biotech collapsed in 2022–24, and spending lags funding by 2–3 quarters).
• Academic/government demand softened on NIH budget uncertainty, grant-timing disruption and a U.S. government shutdown that delayed grant outlays.
• China went from a growth engine to a drag on stimulus digestion, anti-corruption crackdowns and local-competition/geopolitics, before recovering in the last year.
• Layered on top was the post-COVID destock — customers had over-ordered consumables and instruments during 2020–21 and worked down inventory for two years.

This is the same winter that took Avantor (−~70% from peak), Repligen, Revvity, Qiagen, Agilent and the broader group down 30–70%. The competitive set is a mix of diversified giants and specialists: Thermo Fisher and Danaher (the scale leaders), Merck KGaA / MilliporeSigma (the acquirer here — a top-three reagent and bioprocessing player), Revvity, Agilent, Qiagen, Bruker, Sartorius, Bio-Rad, and in spatial biology 10x Genomics, NanoString (bankrupt/acquired), Akoya and Standard BioTools. Bio-Techne is a mid-cap specialist that punches above its weight on margins because of its reagent-heavy mix.

Verdict: structurally good industry (specialty reagents/consumables), cyclically bad recent tape. The demand recession is a cyclical event, not a secular impairment of the reagent moat — which is precisely why a strategic acquirer would buy the trough. The reagent core is attractive; the spatial-biology niche is structurally growing; the diagnostics tail is average. Net: a good industry temporarily out of favor, now consolidating.

4. Competitive Position

Bio-Techne’s moat is real but narrowing, and it is concentrated in one segment. In Greenwald’s taxonomy the durable advantage is an intangible-asset + switching-cost moat in Protein Sciences, with a real-but-contested position in spatial biology and effectively no moat elsewhere.

Protein Sciences — a genuine moat that pays. The R&D Systems catalog of proteins and antibodies is cited in hundreds of thousands of peer-reviewed papers and spec’d into published, validated experimental protocols. Once a specific R&D Systems protein or antibody is written into a paper’s methods and a lab’s workflow, a researcher will not re-validate a cheaper substitute — the reagent cost is trivial next to the cost of an experiment that fails to replicate. That is a textbook validated-in-workflow switching cost, reinforced by an intangible reputation for lot-to-lot consistency and bioactivity that competitors struggle to replicate (there is genuine tacit manufacturing knowledge behind protein production). The moat ties directly to a financial outcome: Protein Sciences held ~70% adjusted gross margins and a stable ~42–44% segment operating margin through a multi-year organic-revenue recession (segment op margin 44.2% / 42.7% / 42.6% FY23–FY25 even as segment sales barely grew). A business that can hold mid-40s operating margins while its end markets shrink has pricing power — the definition of a moat.

Spatial biology (RNAscope / COMET) — real leadership, contested economics. RNAscope (from the 2016 ACD acquisition) is the category-leading in-situ hybridization chemistry, IP-protected and widely adopted; COMET (from Lunaphore, 2023) is a differentiated multiomic spatial platform growing >65%. But this niche is a capital-flooded share war, not yet a profit pool: 10x Genomics (Xenium/Visium), Bruker (which bought bankrupt NanoString for $392.6M in 2024), Akoya and Vizgen are all fighting for a spatial market of only ~$0.64B. The result is the tell in the numbers: Diagnostics & Spatial Biology segment operating margin collapsed from 14.7% (FY23) to 6.2% (FY25) as Bio-Techne funded the build-out. RNAscope’s moat is real; the segment it sits in is not currently paying its cost of capital.

No moat: proteomic-analysis instruments (ProteinSimple/Simple Western/Ella/Maurice — competitive and commoditizing hardware, though they pull recurring consumables), and molecular/clinical diagnostics (lumpy, concentrated, average economics).

The consolidated tell. The moat’s erosion at the corporate level is visible in returns: ROIC fell 12.8% (FY22) → 11.0% → 9.1% → 7.5% (FY25), and ROE from 24.6% to a GAAP-depressed 6.1%. Part of the decline is cyclical (depressed volumes deleveraging a high-fixed-cost base) and part is GAAP distortion (FY25’s $80.5M impairment and $41.8M litigation charge), but part is structural: management diluted a wonderful ~44%-margin reagent business by pouring capital into a sub-scale, ~6%-margin spatial/diagnostics portfolio. The reagent core would clear its cost of capital comfortably on its own; the consolidated entity, in this cycle, barely does.

Head-to-head. Against Thermo Fisher and Danaher (Cytiva/Abcam), Bio-Techne is far smaller but higher-margin in reagents; against Revvity, Qiagen and Agilent it is more consumables-heavy and higher-gross-margin; against pure spatial players (10x) it has a broader, more profitable base but a contested spatial position. Notably, the acquirer — Merck KGaA / MilliporeSigma — is itself a top-three reagent and bioprocessing competitor, which is exactly why the combination has strategic logic and antitrust exposure at once.

Verdict: a durable, high-return moat in the reagent core (Protein Sciences), wrapped in a contested, capital-hungry spatial/diagnostics segment that has diluted consolidated returns. The franchise is genuinely good; the corporate-level economics have deteriorated with scale, not improved — which is why the standalone valuation had de-rated and why a strategic buyer who can graft the reagent moat onto its own platform (and cut the sub-scale overhead) is the natural owner.

5. Growth History and Forward Opportunities

History — a boom-to-bust arc. Revenue compounded impressively over five years in absolute terms — $739M (FY20) → $1,220M (FY25), an ~11% CAGR — but the shape matters more than the average. Organic growth ran ~20%+ in FY21–FY22 (COVID-era demand plus a funding boom), then fell off a cliff: consolidated revenue grew +2.7% (FY23), +2.0% (FY24), +5.2% (FY25), with organic growth of roughly +1% (FY24) and +5% (FY25). Crucially, the nascent FY25 recovery reversed in fiscal 2026: Q3 FY26 (March quarter) organic revenue declined 2%, and nine-month organic was roughly −1%. Within Q3, Protein Sciences organic fell 4% (−2% ex two cell-therapy customers’ order timing and a large OEM order that shifted quarters) while Diagnostics & Spatial Biology grew 3% organic.

Where the growth is (and isn’t). The end-market divergence is stark and is the whole forward debate:

• Large pharma — strong, six consecutive quarters of double-digit growth, driven by discovery, translational and manufacturing spend.
• Emerging biotech — the swing factor, down high-single-digits in Q3 FY26. Biotech funding rebounded sharply (management cited estimate increases of >90% and ~50% in fiscal Q2 and Q3), but spending lags funding by 2–3 quarters, and the funding mix shifted toward late-stage (82% vs. 75% prior), starving the early-discovery work that consumes Bio-Techne’s core reagents. Management expects this to inflect in the first half of fiscal 2027.
• Academia/government — returned to low-single-digit growth as NIH outlays and grant activity improved and a 1% NIH budget increase reduced uncertainty; still frail, not V-shaped.
• China — four consecutive quarters of positive growth after a long slump, with momentum in advanced therapeutics (ADCs, cell therapy, autoimmune).

Structural growth vectors (what Merck is buying).

• GMP proteins for cell & gene therapy — grew ~50% YoY ex two large customers; tied to the G-Rex/Wilson Wolf relationship. Management targets ≥20% sustained growth; 85 clinical programs, progressing from Phase I into II/III.
• Spatial biology — COMET +65% with record backlog; RNAscope high-single-digit and increasingly used in clinical diagnostics; a durable tailwind from AI-driven pathology and content-rich biological datasets.
• Proteomic analysis — Ella (neurodegeneration biomarkers, 3-yr assay CAGR ~50%, now CE-IVD marked) and Maurice (biologics QC, double-digit growth). Management views these instrument franchises as early indicators of an end-market turn.
• AI-adjacent reagent demand — management argues AI-accelerated target discovery ultimately requires biological validation (antibodies, functional assays, recombinant proteins), and that its five decades of proprietary protein data is a defensible input for AI-designed proteins.

Verdict: high-quality growth vectors, currently masked by a cyclical trough. The reagent core is a GDP-plus grower with pricing power; the cell-therapy, spatial and proteomic-analysis franchises are genuine double-digit structural growers. But the consolidated line has been flat-to-negative for a year, and the timing of the biotech inflection is unproven. Management’s mid-single-digit fiscal-2027 base case is credible but not banked — and it is now Merck’s problem, not the public shareholder’s. The growth quality is real; the near-term trajectory is the reason the stock was cheap enough to be bought.

6. Financial Quality

The headline: GAAP earnings are uninterpretable; use adjusted. This is the single most important thing to understand about Bio-Techne’s financials. FY25 GAAP diluted EPS was $0.46 (net income $73.4M), and GAAP operating income was just $102.3M — an 8.4% operating margin, down from 17.8% (FY24) and 26.3% (FY23) — because a stack of one-time charges landed inside operating expenses (SG&A). The company’s own reconciliation bridges GAAP pre-tax income of $98.5M to adjusted pre-tax income of $390.4M, and GAAP EPS of $0.46 to adjusted diluted EPS of $1.92 (FY24 $1.77, FY23 $1.99). The adjustments, in order of size (FY25): an $80.5M impairment of assets held-for-sale (the Exosome Diagnostics write-down ahead of its ~$15M sale); amortization of acquired intangibles ($75.3M) + Wilson Wolf intangible amortization ($10.0M); stock-based compensation ($42.2M); a $41.8M litigation charge — the arbitration with former CEO Charles Kummeth, settled in Q3 FY25 for ~$37.2M cash; and restructuring ($28.2M). Note what is not here: contrary to a common misconception, the company’s Wilson Wolf investment is now carried under the equity method and contributed only ~+$0.9M to FY25 P&L — it is not the source of the GAAP distortion. The distortion is the Exosome impairment, the Kummeth arbitration, amortization and restructuring. Whether one accepts every add-back (SBC is a real economic cost; recurring intangible amortization is defensible to exclude for a serial acquirer, less so if you view M&A as ongoing capex; the arbitration and impairment are genuinely non-recurring), the through-cycle earnings power is clearly the ~$1.90–2.00 adjusted figure, not the $0.46 GAAP number.

Margins — premium, with cyclical erosion. Adjusted gross margin was 70.4% (FY25), down from 71.7% (FY23) on mix (spatial dilution) and lower volume absorption. Adjusted operating margin ran 31.6% (FY25) — low-30s through the cycle — and had recovered to 34.2% in Q3 FY26 (up 310bps sequentially on cost discipline). The contrast between the 8.4% GAAP operating margin and the 31.6% adjusted margin is entirely the one-time impairment/arbitration/restructuring load plus amortization, not core-margin collapse — Protein Sciences segment operating margins barely moved (44.2% → 42.6% FY23–FY25). This is a genuinely high-margin business; the underlying erosion is cyclical volume deleverage plus the spatial/diagnostics drag, not a broken cost structure.

Cash flow — clean and real. Unlike GAAP earnings, cash flow is honest. FY25 operating cash flow was $287.6M on capex of just $31M (a capital-light model — capex ~2.5% of sales), for FCF of ~$257M — roughly 3.9x GAAP net income (a signal of how depressed GAAP NI is) and ~84% of adjusted net earnings. FCF has run $215–310M annually across the cycle. Q3 FY26 OCF was $86.7M on $9.1M capex. This is a business that converts adjusted earnings to cash cleanly and does not need much reinvestment.

Balance sheet — fortress. As of Q3 FY26: cash ~$209.8M, bank debt $200M (down $60M sequentially) plus ~$98M of capital leases, for net debt of roughly $90M — total leverage well below 1x EBITDA. The equity base is ~$1.9B but heavily intangible: goodwill $981M + acquired intangibles $366M = ~$1.35B of the $2.56B asset base, so tangible book is thin (a consequence of a decade of acquisitions). Liquidity, coverage and refinancing risk are all non-issues.

Returns — the deterioration. ROIC fell from 12.8% (FY22) to 7.5% (FY25); ROE from 24.6% to a GAAP-depressed 6.1%. On adjusted earnings the returns are better (adjusted ROIC roughly low-teens), but the trend is unambiguously down — a function of cyclically depressed volumes, a growing goodwill/intangible base, and the sub-scale spatial/diagnostics investment. This is the quantitative signature of a moat that is real at the reagent core but has been diluted at the corporate level.

Verdict: high-quality economics (premium margins, clean FCF conversion, fortress balance sheet) obscured by messy GAAP optics and eroding headline returns. Do the economics improve with scale? Historically yes; over the last three years, no — because the incremental capital went into a lower-return segment during a demand recession. On an adjusted basis this is still a very good business; the returns question is exactly what a strategic buyer with synergies is positioned to fix.

7. Capital Allocation

Capital allocation is where the standalone thesis is weakest — and, not coincidentally, where the activist found its opening. The record is a mix of one genuinely value-creating acquisition, one value-destroying one, opportunistic buybacks, a comp structure that rewards amortization-blind growth, and a looming ~$1B obligation.

M&A — a diversification-by-acquisition strategy with a mixed scorecard. Under long-time CEO Chuck Kummeth, Bio-Techne transformed from a sleepy proteins house into an acquisitive tools platform. The scorecard:

The Exosome episode is the black mark: a $250M liquid-biopsy acquisition (2018) written down and sold for ~$15M (2025) — roughly $235M, or 94%, of capital destroyed. ACD/RNAscope, by contrast, was a clear win. Net, the M&A program bought a decade of revenue growth but at returns that, in aggregate, sit around the cost of capital — the reason consolidated ROIC drifted from ~13% to ~7.5% even before the cyclical trough.

The Wilson Wolf overhang (material). Bio-Techne owns 19.9% of Wilson Wolf Manufacturing (maker of the market-leading G-Rex single-use cell-therapy bioreactor; >70% EBITDA margins), carried at ~$236M under the equity method. Critically, a December-2021 staged forward contract auto-triggered the obligation to acquire the remaining 80.1% by December 31, 2027, at ~4.4x trailing revenue — a ~$1B+ cash call now forecast for FY26–28. This is the single largest capital commitment in the company’s history, and it now becomes Merck’s obligation on close. On a deal-break, it would be Bio-Techne’s — a meaningful call on a ~$90–280M-net-debt balance sheet, and a factor in any standalone valuation.

Capital returns — opportunistic buybacks, token dividend. Repurchases stepped up meaningfully into the price decline: FY21 $43M / FY22 $161M / FY23 $20M / FY24 $80M / FY25 $275.7M — the largest, executed opportunistically into the falling ~$50–70 pre-deal price (good timing, to management’s credit). But diluted share count fell only modestly (161.9M → 159.7M FY21–FY25) because ~$40M/yr of SBC offset much of the repurchase. The dividend is a token $0.08/quarter (~$50M/yr, ~0.5% yield), flat for years. Net debt ~$280M (~0.7x adjusted EBITDA) is low — but the ~$1B Wilson Wolf obligation is the real forward liability.

Compensation & incentives — empire-building-tilted, no ROIC gate. The 2025 proxy shows a structure that would concern a returns-focused owner: the annual bonus is 50% organic revenue + 50% adjusted EBITA, and the long-term performance shares are 3-year adjusted operating income (35%) + relative TSR (25%). Both earnings metrics exclude acquired-intangible amortization — so an acquisition looks accretive on the comp scorecard even when it destroys capital (as Exosome did). Management repeatedly declined to add an ROIC metric despite shareholder requests (“reviewed twice in FY24/FY25,” not adopted) — a governance flag; relative TSR is the only genuine shareholder-alignment lever. New CEO Kim Kelderman and CFO Jim Hippel have leaned toward margin discipline and portfolio simplification, a constructive shift, but the incentive architecture still rewards amortization-blind growth.

Insiders — sellers, no conviction. Across the 163 Form 4s of the last five years, named-officer activity is exclusively option exercises (code M), tax-withholding (code F) and occasional open-market sales (code S). There are zero code-P open-market purchases, including near the ~$43–55 lows of 2025–26 — no insider put personal capital to work at the bottom. Ownership is dispersed (Vanguard ~11.7%, BlackRock ~7.7%, T. Rowe ~6.5%); there is no founder or family control block, which is precisely what made the company vulnerable to an activist and a clean all-cash takeout.

Verdict: capital allocation was the weak link. A wonderful reagent core generated cash that was partly reinvested into value-destructive diversification (Exosome), rewarded by an amortization-blind, no-ROIC comp scheme, while returns fell and insiders sold. Buybacks were well-timed and the balance sheet stayed conservative, but the aggregate return on the M&A program sat near the cost of capital and left a ~$1B Wilson Wolf obligation. This is the record that let Ananym argue the company had “destroyed value for years” — and that made selling to a disciplined strategic the rational outcome for shareholders.

8. Changes and Headwinds — Last Two Years

The last two years contain the entire thesis: a cyclical collapse, a management/strategy reset, and a terminal takeover.

The demand recession (FY23–FY26). The dominant change was the synchronized funding winter across biopharma, academia and China that took organic growth from ~20% to roughly zero. This is a cyclical headwind, and management believes it is bottoming — biotech funding has rebounded, academia has stabilized, and China has grown for four straight quarters — but the inflection in spending has repeatedly proven later than hoped (Q3 FY26 emerging-biotech stepped down, not up).

Leadership and strategy reset. Long-time CEO Chuck Kummeth (who built the modern acquisitive Bio-Techne) handed off to Kim Kelderman (CEO since ~2023), with Jim Hippel as CFO. Under the new team the emphasis shifted from acquisition-led expansion toward margin discipline and portfolio simplification: an April 2026 brand consolidation from ten brands to three (R&D Systems / Bio-Techne Spatial Biology / Bio-Techne Diagnostics), restructuring actions, and portfolio pruning.

Portfolio moves. The most consequential was the divestiture of Exosome Diagnostics (announced August 2025, ~$15M consideration including stock) — a liquid-biopsy molecular-diagnostics business bought years earlier for far more, written down $80.5M as held-for-sale before sale. Its removal is a ~2% reported-revenue headwind but lifted Diagnostics & Spatial Biology segment margins. The Wilson Wolf obligation crystallized: Bio-Techne owns 19.9% and the staged forward contract auto-triggered a requirement to buy the remaining 80.1% (the G-Rex cell-therapy bioreactor line, >70% EBITDA margins) by December 31, 2027 at ~4.4x trailing revenue — a ~$1B+ cash call now inherited by Merck.

Litigation. FY25 carried a $41.8M charge for the arbitration with former CEO Charles Kummeth (settled Q3 FY25 for ~$37.2M cash; added back in the adjusted bridge) — a genuinely non-recurring hit to GAAP earnings.

The activist and the deal. In June 2026, Ananym Capital publicly urged Bio-Techne to explore a sale. Roughly ten days later, on June 25, 2026, the board agreed to sell the company to Merck KGaA for $73.00/share cash. This is the single largest change in the company’s history and supersedes everything else: from the announcement date forward, the stock trades on deal spread and regulatory news, not fundamentals.

Verdict: the headwinds (cyclical demand, eroding returns, a value-destructive Exosome episode) weakened the standalone thesis enough to invite an activist and precipitate a sale; the deal itself is the resolution. For a public shareholder, the relevant “change” is that the fundamental debate has been overtaken by a merger-arbitrage question.

9. Risk Analysis (Risk Matrix)

Because a definitive cash deal is pending, the risk profile has bifurcated: deal-completion risks dominate the next 9–12 months, with the standalone-business risks becoming relevant only if the deal breaks. Both are matrixed below.

The dominant, and arguably only material, risk is antitrust: whether two overlapping reagent/bioprocessing platforms can clear US, EU and other reviews without a divestiture package Merck deems burdensome. The large reverse termination fee ($576M, ~$3.65/share) both signals Merck’s confidence and compensates shareholders partially on a regulatory break — but it caps recovery well below a hypothetical un-impaired standalone value.

The Sigma-Aldrich precedent (directly on point). Merck’s own last large reagent acquisition is the best guide to how this review is likely to go. In 2014–15 Merck bought Sigma-Aldrich for ~$17B ($140/share) — the deal to which the current transaction is the sequel — and the European Commission granted only conditional clearance, requiring Merck to divest Sigma-Aldrich’s European solvents-and-inorganics business (the Seelze, Germany site and the Fluka/Hydranal/Chromasolv brands), which was sold to Honeywell for roughly $105M. The review ran ~14 months (announced September 2014, closed November 2015), and the EU later even charged Merck with providing incomplete information during the process. The read-across is two-sided and, on balance, reassuring for completion: (i) Merck has navigated a major reagent-antitrust review before and accepted divestitures to get the deal done — it does not walk at the first sign of a remedy, which lowers the odds that a targeted divestiture trips the “Burdensome Condition” out; but (ii) a Bio-Techne review will likely follow the same pattern — an EU (and probably FTC) deep-dive with a divestiture package and a ~12–14 month timeline, not a quick clear. That supports the base case (deal closes, with remedies) while validating the ~9–12+ month close assumption baked into the arb’s annualized return. The genuine tail is a broad overlap in research proteins/antibodies or cell-&-gene-therapy reagents that regulators find harder to remedy cleanly than a discrete solvents business — the scenario in which Merck could conclude the required divestitures are burdensome.

10. Valuation — Deal Arithmetic and Embedded Expectations

Valuation here has two distinct frames: (a) the merger-arbitrage math that governs the stock until the deal closes or breaks, and (b) the standalone intrinsic value that determines the deal-break downside and whether $73 is a fair clearing price.

(a) Merger-arbitrage math (the operative frame).

• Deal price: $73.00 cash. Current price: $70.83. Gross spread: $2.17 = ~3.1%.
• Expected timeline to close: ~9–12 months (management/Merck guide to completion within the outside-date window; antitrust of two overlapping platforms plausibly runs to mid-2027). Outside date March 25, 2027, auto-extending to September 25, 2027 for antitrust.
• Annualized gross return: ~3.1% over ~9–12 months ≈ ~3.5–4.5% annualized, plus ~$0.24 of dividends collected en route (~0.3%) → ~4–5% all-in annualized if the deal closes on schedule.
• Deal-break downside: to standalone value ~$50–58 = −20% to −29% from $70.83 (partially cushioned by the $576M reverse fee on a regulatory break).
• Implied completion probability. A simple two-outcome model — p × (+$2.17) − (1−p) × (~$16, to a ~$55 break) ≈ 0 at a risk-free-ish hurdle — implies the market is pricing completion odds in the low-90s%. That is a reasonable read given the board recommendation, activist support, all-cash certainty, the reverse fee, and clear strategic logic; the residual ~5–10% is the antitrust/divestiture tail.

The stock is therefore a thin, positively-skewed-by-probability but negatively-skewed-by-magnitude arb: you risk ~$16 to make ~$2.20, and you are paid ~4–5% annualized to underwrite antitrust clearance. That is an acceptable but unexciting risk-adjusted return — attractive only to those who judge the antitrust risk lower than the ~5–10% the spread implies, or who want a low-market-beta cash-like position.

(b) Is $73 a fair/full price? (embedded expectations). At $73, Bio-Techne is valued at roughly:

• ~9.3x TTM revenue (~$1.21B),
• ~25x adjusted EBITDA (~$450M),
• ~38x trailing adjusted EPS ($1.92), ~35–37x forward adjusted EPS on a fiscal-2027 recovery.

Against the peer group, that is a full, top-of-range multiple: Revvity trades ~4.7x sales / ~17.5x EBITDA, Qiagen ~5.0x / ~14.7x, Agilent ~6.2x / ~24.4x. TECH at 9.3x sales is well above all of them — justified only by (i) its superior ~70% gross margin and ~80% consumables mix, (ii) the cell-therapy/spatial growth optionality, and (iii) Merck’s ~$150M of run-rate cost synergies plus its own MilliporeSigma reagent platform, which let a strategic underwrite a multiple a financial buyer never could. On its own history, $73 (~9.3x sales) is below the 2021–23 range (11–19x sales) but above where the stock traded standalone in this tape (~6.5x sales at the June pre-activist ~$52). In other words, the deal crystallizes a premium the public market was not willing to pay for a zero-growth quarter — a good outcome for holders and a rational, if generous, price for a strategic.

© Standalone intrinsic value (the deal-break anchor). Absent the deal, in the current tape, a name growing ~0% organically with mid-30s adjusted margins, ~$1.90 adjusted EPS, ~7.5% ROIC and a credible-but-unproven fiscal-2027 recovery would trade at roughly 7–8x EV/sales / 19–22x adjusted EBITDA / ~27–30x adjusted EPS — i.e., a ~$50–58 equity price (the pre-activist ~$52 close and the May low of $43 bracket the low end; a recovery-credit toward the high-$50s the high end). A bull standalone case (biotech inflects, spatial scales, margins re-rate) could support the low-$60s over 12–18 months; a bear case (recovery stalls, spatial keeps bleeding) revisits the mid-$40s. This ~$50–58 zone is the deal-break landing spot and the reason the arb’s downside is what it is.

Scenario summary (per share):

Verdict: The operative valuation is the arb: ~4–5% annualized to underwrite antitrust clearance, against a ~20–30% deal-break downside. The $73 price is fair-to-full on the standalone franchise and only rational for a synergy-bearing strategic — which is exactly what it is. No price target; no recommendation (see the Author’s Take above for the labeled view).

11. Variant Perception

Consensus. With the deal announced, sell-side consensus has collapsed to the deal price: a wave of downgrades to Hold/Market-Perform/Neutral with price targets set at $73 (Baird, Stephens, Citi, Benchmark, TD Cowen, William Blair; Piper initiated Neutral just before the deal). The consensus is simply “deal closes at $73” — the ratings now express spread, not fundamental view. The market’s ~3.1% spread encodes high (low-90s%) completion confidence.

The bull case (for the arb). The deal closes on or ahead of schedule. It is board-recommended, activist-endorsed, all-cash, and strategically obvious (Merck’s biggest deal since Sigma-Aldrich in 2015; immediately accretive to sales growth and EBITDA margin, EPS-accretive by year three, $150M synergies). The reagent-market overlap is large but the market is fragmented, and any required remedies are modest and acceptable to Merck. Antitrust clears within ~9 months, the spread compresses to zero, and holders collect ~4–5% annualized plus any early-close acceleration. A small tail: an activist-catalyzed process with a fiduciary out could invite a bump.

The bear case (for the arb). Merck and Bio-Techne are two of the larger suppliers of research reagents, recombinant proteins and cell-&-gene-therapy inputs; a serious EU/FTC review could demand a divestiture package that trips Merck’s “Burdensome Condition” out, and Merck walks (paying $576M). The stock re-rates to standalone value in a still-soft tools tape — low-to-mid $50s, potentially high-$40s — a −20% to −35% outcome. This is the fat tail the thin spread is not richly paying you to bear.

The 3–5 assumptions that matter most.

1. Antitrust clears without a burdensome divestiture (the single swing variable).
2. Merck remains committed — the reverse fee and strategic logic say yes; a macro shock or a change of heart is the low-probability wildcard.
3. Shareholder vote passes (near-certain).
4. Standalone downside is ~$50–58, not lower — depends on the tools tape and biotech-recovery timing at the point of any break.
5. No competing bidder is needed for the base case, but one would be pure upside.

Falsification. The bull (deal-closes) case is falsified by a second request / Phase II EU review that signals a structural-remedy fight, or any Merck statement retreating from “reasonable best efforts.” The bear (deal-break) case is falsified by early HSR clearance / EU unconditional approval, which would compress the spread toward zero.

Factor-positioning read (subordinate to the thesis). Empirically, Bio-Techne is the Life Sciences Tools & Services factor (industry beta ~1.30, r² ~54%; market beta ~1.13–1.24). Its risk-adjusted record is a five-year value-destruction story (−7.9%/yr over five years, −67% lifetime max drawdown) that only turned positive in the last year (+37% 1-yr, driven by the deal pop, m3 ~+213% annualized). But this backward-looking factor signature is now largely moot: post-announcement the stock is a merger-arb instrument pinned near $73, with residual market/factor beta collapsing toward zero. The tape confirms the framing in the Author’s Take — a multi-year falling knife whose decline ended in a takeout rather than a fundamental inflection — but it offers no forward directional signal; the deal spread and the antitrust calendar do.

12. Fact vs. Interpretation

13. Open Questions

1. Antitrust remedy scope. What product overlaps (recombinant proteins, GMP cytokines, specific reagent categories, bioprocessing) will the FTC and European Commission focus on, and is any required divestiture small enough that Merck accepts it rather than invoking the “Burdensome Condition” out? (The single most important open question.)
2. Timeline. Will the parties clear HSR without a second request? EU Phase I vs. Phase II? Chinese SAMR review? Each stage lengthens the close and lowers the annualized arb return.
3. Topping bid. Does the activist-catalyzed, fiduciary-out process invite any competing strategic interest (Thermo, Danaher) — or does the same-or-worse antitrust exposure for any large tools acquirer preclude a counter-bid?
4. Standalone downside precision. If the deal breaks in (say) mid-2027, where is the tools tape and the biotech recovery — i.e., is the break level closer to $58 or to $45?
5. Wilson Wolf on a break. How would the staged Wilson Wolf acquisition (20% owned, buyout due by end-CY2027) and its fair-value liability behave if TECH remained independent?
6. Insider / large-holder behavior post-announcement. Are there Form 4 dispositions or 13D/G changes signaling arb-fund accumulation or informed-holder exit? (Being finalized by the SEC sweep.)

14. What Must Be True

For the deal (base) case to pay (stock → $73):

• Antitrust and foreign-investment clearances (HSR, EU, and others) are obtained without a divestiture package Merck deems burdensome; falsification test: a second request / EU Phase II with structural-remedy demands, or any Merck retreat from “reasonable best efforts,” signals the tail is materializing.
• The shareholder vote passes (near-certain given a 36% premium, board + activist support, all-cash); falsification: a proxy advisor or large holder agitates for more — low odds, and would more likely produce a bump than a break.
• Merck remains committed through close; falsification: a macro/financing shock or strategic reversal (the reverse fee makes this expensive and unlikely).

For the bear (deal-break) case (stock → ~$50–58 or lower):

• Regulators demand remedies large enough to trip the Burdensome Condition, or a court enjoins the deal; Merck terminates and pays the $576M reverse fee; falsification test: early unconditional clearances that compress the spread toward zero.
• On the break, the standalone franchise re-rates in a still-soft tools tape — organic growth has not yet inflected, spatial margins remain depressed, and the multiple normalizes toward the peer range; falsification: a sharp biotech-spending recovery and spatial-margin inflection that would let the standalone equity re-rate toward the low-$60s rather than the low-$50s.

The elegance — and the limit — of the situation is that both cases hinge on the same fact pattern: the antitrust review of two overlapping reagent platforms. Everything else is near-decided.

APPENDIX A — Standard Diligence Questionnaire

Standard Diligence Questionnaire — Bio-Techne Corporation (NASDAQ: TECH)

Supplemental appendix to this article, dated 2026-07-03. Fact / Interpretation / Assumption labels where material. Context: a definitive all-cash merger with Merck KGaA at $73.00/share (announced 2026-06-25) is pending; several answers below are framed against that reality.

General

What thoughtful questions have other investors asked about this company? (1) Will the antitrust review of two overlapping reagent/bioprocessing platforms (Merck/MilliporeSigma + Bio-Techne) clear without a divestiture that trips Merck’s “Burdensome Condition” out? (2) Is $73 a fair price, or did an activist force a sale at a cyclical trough? (3) When does the biotech-spending recovery actually inflect (it has been “next fiscal year” for several quarters)? (4) Is the spatial-biology investment (Lunaphore/COMET) ever going to earn its cost of capital, or is it a share war? (5) What is the true cost and timing of the ~$1B Wilson Wolf buyout? (6) How much of the historical “growth” was acquired vs. organic, and did the M&A create value?

Cyclicality & Earnings Nature

• Cyclical high or low? Low (Fact/Interp). Organic growth went from ~20% (FY21–22) to −2% (Q3 FY26); biopharma, academic and China end markets are at/near cyclical troughs. Earnings are cyclically depressed, not peak.
• External environment or internal actions? Predominantly external (biotech-funding winter, NIH/academic austerity, China down-cycle, post-COVID destock), amplified by internal one-time charges (Exosome impairment, Kummeth arbitration).
• Revenue stability? ~80% consumables (single-use reagents) provides a recurring, sticky base; instruments (~9%) and biotech-linked demand are the volatile layer.
• Outlook for products/services? Core reagents = GDP-plus with pricing power; cell-therapy GMP proteins, spatial biology and proteomic analysis = structural double-digit growers; diagnostics = low-growth/lumpy.
• Market size / direction? Life-science tools/reagents is a large, growing, global market; spatial genomics is small (~$0.64B) but growing ~12–13%/yr. Mostly international; ~56% US, ~6% mainland China.

Business Quality & Competitive Moat

• Industry more or less competitive? More competitive in spatial biology (10x, Bruker/NanoString, Akoya) and diagnostics; stable oligopoly in premium reagents.
• Profitability (ROIC/ROE)? Adjusted operating margin ~31.6% (FY25); GAAP ROIC fell 12.8% (FY22) → 7.5% (FY25); GAAP ROE 6.1% (impairment-depressed). Adjusted returns are better (low-teens) but declining.
• Industry profitability / barriers? Premium reagents: high barriers (validated proteins, citation lock-in, GMP manufacturing, tacit knowledge). Spatial/dx: lower barriers, capital-flooded.
• Easily understood? Reasonably — a razor/razor-blade reagents-and-instruments model. GAAP optics are the complicating factor.
• Undermined by low-cost foreign labor? No — the moat is scientific validation and consistency, not labor cost; low-price competitors exist but lose at the premium end.
• Do brands matter? Yes — R&D Systems and RNAscope are trusted, cited brands; the April-2026 consolidation to three brands reinforces this.
• Nature of competition? Quality/validation-based at the premium end; price/technology-based in instruments and spatial.
• Switching costs? High in the reagent core (re-validating a substitute reagent risks experimental reproducibility); low in instruments.

Financial Condition & Balance Sheet

• Assets not fully on the balance sheet? The R&D Systems brand/citation moat and ~50 years of proprietary protein data are not capitalized (internally generated). The 19.9% Wilson Wolf stake is at ~$236M equity-method carrying value.
• Off-balance-sheet liabilities? The ~$1B+ obligation to acquire the remaining 80.1% of Wilson Wolf by end-2027 is the key forward commitment (a contractual forward, not a normal liability today). On close it becomes Merck’s.
• How conservative is the accounting? Cash flow is clean and conservative; GAAP earnings are noisy but the noise is disclosed one-time charges + amortization, not aggressive revenue recognition. Adjusted metrics exclude a lot (amortization, SBC) — read both.
• CapEx-hungry? No — capital-light; capex ~2.5% of sales (~$31M FY25).

Capital Allocation & Management

• FCF generation / use / philosophy? ~$257M FCF (FY25); used for M&A (primary), opportunistic buybacks (FY25 $276M into the decline), and a token dividend. Philosophy was growth-by-acquisition; new management leans toward margin/portfolio discipline.
• Significant acquisitions recently? Lunaphore ($169.7M, FY24), Namocell ($101.2M, FY23); the staged Wilson Wolf. Historically ACD ($325M, win) and Exosome ($250M → sold ~$15M, ~94% destroyed).
• Buying back shares? Yes, opportunistically (FY25 $276M), but SBC (~$40M/yr) offsets much of it — net share count fell only modestly.
• Issuing shares to insiders? ~$40M/yr SBC; no unusual insider issuance.
• Compensation policy? Bonus = 50% organic revenue + 50% adjusted EBITA; LTI = 3-yr adjusted operating income (35%) + relative TSR (25%). Both earnings metrics exclude acquired-intangible amortization; no ROIC gate despite shareholder requests — a governance flag.
• Management motivations? Comp rewards amortization-blind growth; relative TSR is the only genuine alignment. Insiders were net sellers (zero code-P buys at the lows). Activist pressure (Ananym) catalyzed the sale.

Valuation & Market Data

• ADR / MLP / K-1? No — a Minnesota C-corporation, common stock, 1099 (not K-1).
• Dividend policy? $0.08/quarter (~$0.32/yr), ~0.5% yield, flat for years; token.
• How profitable? High-margin on an adjusted basis (70% gross, ~32% operating); GAAP-depressed.
• Net income diverging from cash from operations? Yes, materially — FY25 OCF ($288M) was ~3.9x GAAP net income ($73M) because GAAP NI is loaded with non-cash/one-time charges. Cash is the truer signal.

Risks & Downside

• What would cause the stock to decline? A deal break (antitrust) → re-rate to ~$50–58 (−20% to −29%); a burdensome-divestiture demand; (deal-break) a prolonged biotech/academic/China weakness or spatial-margin bleed.
• Catastrophic loss risk? Low — fortress balance sheet (<1x leverage), no solvency risk; downside is bounded by standalone intrinsic value, cushioned partly by the $576M reverse termination fee on a regulatory break.
• Total loss? Effectively nil.

Recent News & Events

• Business environment changed recently? Yes — (1) the defining event: Merck KGaA agreed to acquire TECH for $73/share cash on 2026-06-25; (2) activist Ananym pushed for a sale ~2026-06-15; (3) Exosome Diagnostics divested (FY26); (4) brand consolidation 10→3 (April 2026); (5) end markets stabilizing (academia, China) but emerging biotech still soft.
• Significant acquisitions/divestitures? Divested Exosome; the ~$1B Wilson Wolf buyout looms (now Merck’s).
• Accounting-policy changes? Adopted new segment-reporting disclosure (ASU 2023-07); renamed the second segment to “Diagnostics and Spatial Biology.”
• Other recent changes? New CEO (Kim Kelderman) and CFO (Jim Hippel); restructuring; CE-IVD marking for Ella; first COMET install in China.

APPENDIX B — Source Appendix

Source Appendix — Bio-Techne Corporation (NASDAQ: TECH)

Compiled for this article, dated 2026-07-03. Primary sources first; every non-obvious fact traces to a public source listed here. Accessed July 2–3, 2026.

A. Merger / primary deal documents (the operative event)

1. Form 8-K, filed 2026-06-26 (event date 2026-06-25), Item 1.01 — Agreement and Plan of Merger with Merck KGaA (Darmstadt, Germany) and EMD Holdings NewCo, Inc. Merger consideration $73.00/share cash; closing conditions (majority MN shareholder vote; HSR + scheduled antitrust/FDI approvals; no injunction; “Burdensome Condition” carve-out); no-shop with fiduciary out; Company termination fee $230,455,000; Parent (reverse) termination fee $576,140,000; Outside Date March 25, 2027 (auto-extends to June 25 then Sept 25, 2027 for antitrust). SEC EDGAR, CIK 0000842023. https://www.sec.gov/Archives/edgar/data/842023/000199937126013527/tech-8k_062326.htm
2. Form 8-K, filed 2026-06-25, Item 7.01 + Exhibit 99.1 — joint Merck/Bio-Techne press release announcing the transaction. https://www.sec.gov/Archives/edgar/data/842023/000199937126013429/ex99-1.htm
3. DEFA14A, filed 2026-06-25 — soliciting materials (Rule 14a-12) re: the merger. SEC EDGAR.
4. Merck KGaA / Bio-Techne press release — “Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne…” — EV ~$11.3B (€9.9B), 36% premium to 1-month VWAP, ~$150M (€140M) run-rate cost synergies within 3 years, immediately accretive to sales growth and EBITDA margin, EPS-accretive in year 3. PR Newswire, 2026-06-25. https://www.prnewswire.com/news-releases/merck-kgaa-darmstadt-germany-agrees-to-acquire-bio-techne-strengthening-leadership-position-in-fast-growing-life-sciences-markets-302810602.html
5. FiercePharma — “Merck KGaA throws down $11.3B for Bio-Techne in its biggest deal since 2015 Sigma-Aldrich buy,” 2026-06-25. https://www.fiercepharma.com/pharma/merck-kgaa-throws-down-113b-bio-techne-biggest-deal-2015-sigma-aldrich-buy
6. Activist context — Bloomberg/press: “Activist Investor Ananym Urges Bio-Techne to Consider Selling,” ~2026-06-15.

B. SEC filings — financials & governance (5-year corpus, CIK 0000842023)

7. Form 10-K FY2025 (period ended 2025-06-30), filed 2025-08-22 — segment note (Protein Sciences / Diagnostics & Spatial Biology), non-GAAP reconciliation (adjusted diluted EPS $1.92; adjusted pre-tax $390.4M), gross-margin history, geography, Exosome held-for-sale disclosure, Wilson Wolf.
8. Form 10-Q Q3 FY2026 (period ended 2026-03-31), filed 2026-05-06 — latest quarterly financials.
9. Forms 10-K FY2021–FY2024 — trend data.
10. DEF 14A (proxy) 2025 and prior — executive compensation metrics, insider ownership, incentive design.
11. Forms 3/4/5 — insider-transaction corpus (163 Form 4s).
12. Forms 8-K FY2021–FY2026 — earnings releases, executive/board changes, material events.

C. Earnings call

13. Q3 FY2026 earnings call transcript, 2026-05-06 — CEO Kim Kelderman, CFO Jim Hippel. Revenue $311.4M (−2% organic), adjusted EPS $0.53, adjusted operating margin 34.2%; end-market and segment detail; Wilson Wolf update (20% owned, buyout by end-CY2027); brand consolidation 10→3. Via ROIC.ai transcript tools.

D. Quantitative data feeds (third-party; reconciled to filings)

14. ROIC.ai MCP — income statement, balance sheet, cash flow, profitability/valuation ratios, enterprise value (TECH and peers RVTY, QGEN, A). Third-party aggregated; EDGAR primary.
15. AZI price CSV (azitrading.com) — split/dividend-adjusted daily OHLCV, 1989–2026; used for the five-year event map and price levels.
16. AZI valuation_index — own-history percentile ranks (composite 54th; P/S 37.7th, P/B 35.7th; P/E 89th distorted by amortization-depressed GAAP EPS).
17. AZI news feed — deal timeline and analyst-action tape (downgrades to $73 post-announcement).
18. FactorsToday — factor loadings (Life Sciences Tools & Services industry beta ~1.30, r² ~54%; market beta ~1.13–1.24), leaderboard (5-yr −7.9%/yr, lifetime max drawdown −67%, 1-yr +37%), related-stocks comp cross-check (WAT, CRL, IQV, A, TMO, DHR).

E. Industry / competitive context

19. MarketsandMarkets — spatial genomics/transcriptomics market sizing (~$0.64B, ~12.6% CAGR). https://www.marketsandmarkets.com/ResearchInsight/spatial-genomics-transcriptomics-market.asp
20. GEN (Genetic Engineering & Biotechnology News) — “Merck KGaA to Acquire Bio-Techne for $11.3B,” 2026-06-25.
21. Bruker/NanoString acquisition ($392.6M, 2024) — spatial-biology competitive context (trade press). 21a. Merck/Sigma-Aldrich antitrust precedent — European Commission conditional clearance (June 2015) of Merck’s ~$17B Sigma-Aldrich acquisition required divestiture of the European solvents/inorganics business (Seelze; Fluka/Hydranal/Chromasolv) to Honeywell (~$105M); deal closed Nov 2015; ~14-month review. PR Newswire / DCAT / chemeurope; and C&EN (2017) on the EU’s subsequent information-completeness charge. https://www.dcatvci.org/top-industry-news/sigma-aldrich-agrees-to-divest-parts-of-solvents-and-inorganics-business-in-europe-in-merck-kgaa-s-17-bn-acquisition-bid/

Note: analyst price targets and third-party ratings are cited as market context only and are never adopted as an view or price target. ROIC.ai / AZI / FactorsToday figures are third-party estimates reconciled to primary filings where material.